Cargando…

Inflammation Status and Body Composition Predict Two-Year Mortality of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma under Provision of Recommended Energy Intake during Concurrent Chemoradiotherapy

Only few prospective cohort trials have evaluated the risk factors for the 2-year mortality rate between two patient subgroups with locally advanced head and neck squamous cell carcinoma (LAHNSCC): oral cavity cancer with adjuvant concurrent chemoradiotherapy (CCRT) (OCC) and non-oral cavity cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yu-Ching, Wang, Cheng-Hsu, Ling, Hang Huong, Pan, Yi-Ping, Chang, Pei-Hung, Chou, Wen-Chi, Chen, Fang-Ping, Yeh, Kun-Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962429/ https://www.ncbi.nlm.nih.gov/pubmed/35203597 http://dx.doi.org/10.3390/biomedicines10020388

Ejemplares similares

Concurrent Chemoradiotherapy Induces Body Composition Changes in Locally Advanced Head and Neck Squamous Cell Carcinoma: Comparison between Oral Cavity and Non-Oral Cavity Cancer
por: Lin, Yu-Ching, et al.
Publicado: (2021)

Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision
por: Wang, Chao-Hung, et al.
Publicado: (2022)

Determining Malnutrition Assessment Criteria to Predict One-Year Mortality for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy
por: Ling, Hang Huong, et al.
Publicado: (2020)

Comorbidity, Radiation Duration, and Pretreatment Body Muscle Mass Predict Early Treatment Failure in Taiwanese Patients with Locally Advanced Oral Cavity Squamous Cell Carcinoma after Completion of Adjuvant Concurrent Chemoradiotherapy
por: Lin, Yu-Ching, et al.
Publicado: (2021)

Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer
por: Chang, Pei-Hung, et al.
Publicado: (2017)

Impact of Diabetes Mellitus on Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy
por: Kuo, Hsuan-Chih, et al.
Publicado: (2020)

Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis
por: Zhang, Lijuan, et al.
Publicado: (2015)

Clinical Significance of Frailty on Treatment Outcome in Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy
por: Chou, Wen-Chi, et al.
Publicado: (2022)

Role of the Appendicular Skeletal Muscle Index for Predicting the Recurrence-Free Survival of Head and Neck Cancer
por: Yeh, Kun-Yun, et al.
Publicado: (2021)

Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2017)

The Impact of Clinical Prognosis of Viral Hepatitis in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy
por: Wang, Yu-Ming, et al.
Publicado: (2023)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma
por: Huo, Rui-Xue, et al.
Publicado: (2022)

Efficacy of Different Chemotherapy Regimens in Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2020)

Change of Swallowing in Patients With Head and Neck Cancer After Concurrent Chemoradiotherapy
por: Kweon, Sehi, et al.
Publicado: (2016)

The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy
por: Wang, Hui-Ching, et al.
Publicado: (2023)

The provision of enteral nutritional support during definitive chemoradiotherapy in head and neck cancer patients
por: Bishop, Sarah, et al.
Publicado: (2015)

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
por: Kim, J G, et al.
Publicado: (2005)

Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
por: Ho, Yu-Chieh, et al.
Publicado: (2023)

Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy
por: Fujii, Masami, et al.
Publicado: (2015)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity
por: Tsukuda, Mamoru, et al.
Publicado: (2009)

Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience
por: Rawat, Shyamji, et al.
Publicado: (2019)

Competing Morbidities In Advanced Head And Neck Squamous Cell Carcinoma Concurrent Chemoradiotherapy: A Strong Implication Of A Multidisciplinary Team Approach
por: Lazzari, Grazia, et al.
Publicado: (2019)

Chemoradiotherapy for Head and Neck Cancer
por: D’Onofrio, Ida, et al.
Publicado: (2023)

Phytochemical-rich vegetable and fruit juice alleviates oral mucositis during concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
por: Chang, Hui-Ping, et al.
Publicado: (2022)

Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
por: Shirasu, Hiromichi, et al.
Publicado: (2020)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Feasibility and Efficacy of Inspiratory Muscle Training in Patients with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy
por: Vira, Prina, et al.
Publicado: (2021)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Acupoint stimulation improves pain and quality of life in head and neck cancer patients with chemoradiotherapy: A randomized controlled trial
por: Chou, Ya-Hui, et al.
Publicado: (2021)

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Thai Hoa, Nguyen Thi, et al.
Publicado: (2020)

Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison
por: Soo, K-C, et al.
Publicado: (2005)

Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma
por: Yi, Junlin, et al.
Publicado: (2017)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
por: Bagri, Puneet Kumar, et al.
Publicado: (2014)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma
por: Tsou, Yung-Kuan, et al.
Publicado: (2017)

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Katori, H, et al.
Publicado: (2004)

Treatment outcomes in poor metabolizers of cytochrome P450 2A6 with concurrent chemoradiotherapy in locally advanced head- and neck-squamous cell carcinoma
por: Aggarwal, Deepa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ql7ca8d7g4rofbp4v37phdhln